Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 4/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | FECH | P22830 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633885 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1633728 | 0.88 | LMNA (0.40) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1633727 | 0.88 | LMNA (0.40) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634424 | 0.86 | CYP1A2 (0.43) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634807 | 0.84 | PLK1 (0.39) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634806 | 0.84 | PLK1 (0.39) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1635887 | 0.84 | PLK1 (0.39) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634057 | 0.83 | LMNA (0.43) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634052 | 0.83 | LMNA (0.43) | SMN1; SMN2LMNAHTTALOX15MAPK1 | |
| SCHEMBL1634070 | 0.83 | TRPV1 (0.50) | SMN1; SMN2LMNAALDH1A1ABCG2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | claimed |
| EP-3138832-A1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | SMN1; SMN2 2736/4885LMNA 2048/4885HTT 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.